

DOCKET NO.: ISIS0040-100 (RTS-0303)**PATENT****In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 3 and 27 and amend claim 1 as follows:

1. (Currently amended) A compound 8 to 50 nucleobases in length targeted to the 3' untranslated region of a nucleic acid molecule encoding B-cell associated protein (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding B-cell associated protein and inhibits the expression of B-cell associated protein.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Cancelled)
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

DOCKET NO.: ISIS0040-100 (RTS-0303)**PATENT**

9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (Original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding B-cell associated protein.
12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15. (Original) A method of inhibiting the expression of B-cell associated protein in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of B-cell associated protein is inhibited.
16. (Original) A method of treating an animal having a disease or condition associated with B-cell associated protein comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of B-cell associated protein is inhibited.
17. (Original) The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

DOCKET NO.: ISIS0040-100 (RTS-0303)**PATENT**

18. (Original) The method of claim 17 wherein the hyperproliferative disorder is cancer.
19. (Original) The method of claim 18 wherein the cancer is selected from the group consisting of breast cancer and prostate cancer.
20. (Original) The method of claim 16 wherein the disease or condition is characterized by altered levels of apoptosis.
21. (Previously presented) The compound of claim 1 wherein the compound specifically hybridizes to the 5' untranslated region, the start codon region, the coding region, the stop codon region, or the 3' untranslated region of the nucleic acid molecule encoding B-cell associated protein.
22. (Previously presented) The compound of claim 21 wherein the compound specifically hybridizes to the 5' untranslated region.
23. (Previously presented) The compound of claim 1 wherein the compound specifically hybridizes to the start codon region.
24. (Previously presented) The compound of claim 1 wherein the compound specifically hybridizes to the coding region.
25. (Previously presented) The compound of claim 1 wherein the compound specifically hybridizes to the stop codon region.
26. (Previously presented) The compound of claim 1 wherein the compound specifically hybridizes to the 3' untranslated region.
27. (Cancelled)